MLYS

Mineralys Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 3/10
  • Value↑ 6/10
Mineralys Therapeutics sales and earnings growth
MLYS Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 46.38%
  • FCF Y/Y↑ 29.21%
Mineralys Therapeutics gross and profit margin trends
MLYS Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -68.99%
Mineralys Therapeutics net debt vs free cash flow
MLYS Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Mineralys Therapeutics stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks